baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC BON.CAP.CERT. 09/24 AMD/ DE000HD3TH27 /

5/16/2024 9:46:29 PM	Chg.+4.890	Bid9:59:38 PM	Ask9:59:38 PM	Underlying	Strike price	Expiration date	Option type
204.260EUR	+2.45%	203.650 Bid Size: 500	203.660 Ask Size: 500	Advanced Micro Devic...	- USD	9/27/2024	Call

Newsfile Corp 5/16 FDA Grants AI-Powered Notal Vision Home OCT "SCANLY" De Novo Marketing Authorization

GlobeNewswire 5/15 Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Cor...

GlobeNewswire 5/14 AMD Announces Upcoming Events for the Financial Community

GlobeNewswire 5/14 Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facilit...

GlobeNewswire 5/14 Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 5/13 Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5...

GlobeNewswire 5/13 AMD Remains the Partner of Choice for World’s Fastest and Most Efficient High Performance Computing ...

GlobeNewswire 5/9 Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 5/9 Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlight...

GlobeNewswire 5/9 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights

GlobeNewswire 5/8 Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progress...

GlobeNewswire 5/8 Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegener...

GlobeNewswire 5/8 AMD Receives IEEE 2024 Corporate Innovation Award for Leadership in Chiplet Design for High-Performa...

GlobeNewswire 5/8 Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results

GlobeNewswire 5/8 EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporat...

GlobeNewswire 5/7 Ocular Therapeutix™ Reports First Quarter 2024 Results

GlobeNewswire 5/7 Optiver Chooses AMD Enterprise Portfolio to Power its Data Center Modernization, Enabling New Era of...

GlobeNewswire 5/7 Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results

GlobeNewswire 5/7 Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 5/6 Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD

GlobeNewswire 5/6 Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease ...

GlobeNewswire 5/6 Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at th...

GlobeNewswire 5/6 Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

GlobeNewswire 5/6 EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Prol...

GlobeNewswire 5/3 Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

UC BON.CAP.CERT. 09/24 AMD/ DE000HD3TH27 /

If you wish to receive reply to your feedback, please provide your email address.